Skip to main content Accessibility help
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 8 - Epigenomic code

from Part 3 - Events responsible for aberrant genetic and epigenetic codes in cancer


1. Kaminsky ZA, Tang T, Wang SC, et al. 2009. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet 41:240–5.
2. Fraga MF, Ballestar E, Paz MF, et al. 2005. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102:10604–9.
3. Humpherys D, Eggan K, Akutsu H, et al. 2001. Epigenetic instability in ES cells and cloned mice. Science 293:95–7.
4. Bird A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21.
5. Bird A. 2007. Perceptions of epigenetics. Nature 447:396–8.
6. Jaenisch R, Bird A. 2003. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 Suppl:245–54.
7. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128:693–705.
8. Chen K, Rajewsky N. 2007. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 8:93–103.
9. Fraser P, Bickmore W. 2007. Nuclear organization of the genome and the potential for gene regulation. Nature 447:413–7.
10. Zaratiegui M, Irvine DV, Martienssen RA. 2007. Noncoding RNAs and gene silencing. Cell 128:763–76.
11. Bernstein BE, Meissner A, Lander ES. 2007. The mammalian epigenome. Cell 128:669–81.
12. Christensen BC, Houseman EA, Marsit CJ, et al. 2009. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 5:e1000602.
13. Jirtle RL, Skinner MK. 2007. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8:253–62.
14. Weaver IC, Cervoni N, Champagne FA, et al. 2004. Epigenetic programming by maternal behavior. Nat Neurosci 7:847–54.
15. Weidman JR, Dolinoy DC, Murphy SK, Jirtle RL. 2007. Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer J 13:9–16.
16. Esteller M. 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–98.
17. Esteller M. 2008. Epigenetics in cancer. N Engl J Med 358:1148–59.
18. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683–92.
19. Laird PW. 2005. Cancer epigenetics. Hum Mol Genet 14 Spec No 1:R65–76.
20. Robertson KD. 2005. DNA methylation and human disease. Nat Rev Genet 6:597–610.
21. Ehrlich M. 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21:5400–13.
22. Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. Nat Rev Cancer 4:143–53.
23. Plass C. 2002. Cancer epigenomics. Hum Mol Genet 11:2479–88.
24. Fraga MF, Esteller M. 2002. DNA methylation: a profile of methods and applications. Biotechniques 33:632, 634, 636–49.
25. Laird PW. 2003. The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253–66.
26. Lyko F. 2005. Novel methods for analysis of genomic DNA methylation. Anal Bioanal Chem 381:67–8.
27. Shames DS, Minna JD, Gazdar AF. 2007. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 251:187–98.
28. Shen L, Waterland RA. 2007. Methods of DNA methylation analysis. Curr Opin Clin Nutr Metab Care 10:576–81.
29. Frommer M, McDonald LE, Millar DS, et al. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827–31.
30. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–6.
31. Frigola J, Ribas M, Risques RA, Peinado MA. 2002. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res 30:e28.
32. Kawai J, Hirotsune S, Hirose K, et al. 1993. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res 21:5604–8.
33. Ramsay G. 1998. DNA chips: state-of-the art. Nat Biotechnol 16:40–4.
34. Adrien LR, Schlecht NF, Kawachi N, et al. 2006. Classification of DNA methylation patterns in tumor cell genomes using a CpG island microarray. Cytogenet Genome Res 114:16–23.
35. Ching TT, Maunakea AK, Jun P, et al. 2005. Microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet 37:645–51.
36. Zhang X, Yazaki J, Sundaresan A, et al. 2006. Genome-wide high-resolution mapping and functional analysis of DNA methylation in Arabidopsis. Cell 126:1189–201.
37. Weber M, Davies JJ, Wittig D, et al. 2005. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37:853–62.
38. Gebhard C, Schwarzfischer L, Pham TH, et al. 2006. Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res 34:e82.
39. Gebhard C, Schwarzfischer L, Pham TH, et al. 2006. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 66:6118–28.
40. Huang TH, Perry MR, Laux DE. 1999. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8:459–70.
41. Khulan B, Thompson RF, Ye K, et al. 2006. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 16:1046–55.
42. Adorjan P, Distler J, Lipscher E, et al. 2002. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res 30:e21.
43. Bibikova M, Chudin E, Wu B, et al. 2006. Human embryonic stem cells have a unique epigenetic signature. Genome Res 16:1075–83.
44. Bibikova M, Lin Z, Zhou L, et al. 2006. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16:383–93.
45. Martin-Subero JI, Kreuz M, Bibikova M, et al. 2009. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113:2488–97.
46. Karpf AR. 2007. Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr Opin Mol Ther 9:231–41.
47. Shames DS, Girard L, Gao B, et al. 2006. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3:e486.
48. Fraga MF, Ballestar E, Villar-Garea A, et al. 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400.
49. Seligson DB, Horvath S, Shi T, et al. 2005. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–6.
50. Bernstein BE, Humphrey EL, Liu CL, Schreiber SL. 2004. The use of chromatin immunoprecipitation assays in genome-wide analyses of histone modifications. Methods Enzymol 376:349–60.
51. Huebert DJ, Kamal M, O'Donovan A, Bernstein BE. 2006. Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 40:365–9.
52. Fan JB, Chee MS, Gunderson KL. 2006. Highly parallel genomic assays. Nat Rev Genet 7:632–44.
53. Margulies M, Egholm M, Altman WE, et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376–80.
54. Shendure J, Porreca GJ, Reppas NB, et al. 2005. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309:1728–32.
55. Fernandez AF, Rosales C, Lopez-Nieva P, et al. 2009. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19:438–51.
56. Lister R, O'Malley RC, Tonti-Filippini J, et al. 2008. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133:523–36.
57. Cokus SJ, Feng S, Zhang X, et al. 2008. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 452:215–9.
58. Barski A, Cuddapah S, Cui K, et al. 2007. High-resolution profiling of histone methylations in the human genome. Cell 129:823–37.
59. Robertson AG, Bilenky M, Tam A, et al. 2008. Genome-wide relationship between histone H3 lysine 4 mono- and tri-methylation and transcription factor binding. Genome Res 18:1906–17.
60. Wang Z, Zang C, Rosenfeld JA, et al. 2008. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40:897–903.
61. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S. 2002. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 21:4183–95.
62. Rhee I, Bachman KE, Park BH, et al. 2002. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552–6.
63. Rhee I, Jair KW, Yen RW, et al. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404:1003–7.
64. Paz MF, Wei S, Cigudosa JC, et al. 2003. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 12:2209–19.
65. Jacinto FV, Ballestar E, Ropero S, Esteller M. 2007. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 67:11481–6.
66. Ballestar E, Esteller M. 2005. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol 83:374–84.
67. Fraga MF, Ballestar E, Montoya G, et al. 2003. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 31:1765–74.
68. Ballestar E, Paz MF, Valle L, et al. 2003. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22:6335–45.
69. Klose RJ, Sarraf SA, Schmiedeberg L, et al. 2005. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 19:667–78.
70. Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. 2006. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 66:8342–6.
71. Jones PL, Veenstra GJ, Wade PA, et al. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187–91.
72. Nan X, Ng HH, Johnson CA, et al. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386–9.
73. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 20:2536–44.
74. Robertson KD, Ait-Si-Ali S, Yokochi T, et al. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338–42.
75. Fuks F, Hurd PJ, Deplus R, Kouzarides T. 2003. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31:2305–12.
76. Fuks F, Hurd PJ, Wolf D, et al. 2003. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278:4035–40.
77. Vire E, Brenner C, Deplus R, et al. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871–4.
78. Bestor TH. 2005. Transposons reanimated in mice. Cell 122:322–5.
79. Shen L, Kondo Y, Guo Y, et al. 2007. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet 3:2023–36.
80. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293:1074–80.
81. Eckhardt F, Lewin J, Cortese R, et al. 2006. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 38:1378–85.
82. Grunau C, Hindermann W, Rosenthal A. 2000. Large-scale methylation analysis of human genomic DNA reveals tissue-specific differences between the methylation profiles of genes and pseudogenes. Hum Mol Genet 9:2651–63.
83. Strichman-Almashanu LZ, Lee RS, Onyango PO, et al. 2002. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res 12:543–54.
84. Weber M, Hellmann I, Stadler MB, et al. 2007. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457–66.
85. Meissner A, Mikkelsen TS, Gu H, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766–70.
86. Reik W, Walter J. 2001. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2:21–32.
87. Bernstein BE, Mikkelsen TS, Xie X, et al. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315–26.
88. Azuara V, Perry P, Sauer S, et al. 2006. Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8:532–8.
89. Sparmann A, van Lohuizen M. 2006. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–56.
90. Esteller M. 2006. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94:179–83.
91. Feinberg AP, Vogelstein B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89–92.
92. Eden A, Gaudet F, Waghmare A, Jaenisch R. 2003. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455.
93. Gaudet F, Hodgson JG, Eden A, et al. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300:489–92.
94. Karpf AR, Matsui S. 2005. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 65:8635–9.
95. Ehrlich M. 2003. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 109:17–28.
96. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. 2008. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27:404–8.
97. Feinberg AP. 1999. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 59:1743s–6s.
98. Bodey B. 2002. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy. Expert Opin Biol Ther 2:577–84.
99. Martinez R, Martin-Subero JI, Rohde V, et al. 2009. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4:255–64.
100. Martin-Subero JI, Ammerpohl O, Bibikova M, et al. 2009. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 4:e6986.
101. Paz MF, Fraga MF, Avila S, et al. 2003. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63:1114–21.
102. Esteller M. 2007. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1:R50–R9.
103. Costello JF, Fruhwald MC, Smiraglia DJ, et al. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132–8.
104. Esteller M, Fraga MF, Guo M, et al. 2001. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:3001–7.
105. Grady WM, Willis J, Guilford PJ, et al. 2000. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26:16–17.
106. Piotrowski A, Benetkiewicz M, Menzel U, et al. 2006. Microarray-based survey of CpG islands identifies concurrent hyper- and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer 45:656–67.
107. Versmold B, Felsberg J, Mikeska T, et al. 2007. Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. Int J Cancer 121:547–54.
108. Yan PS, Chen CM, Shi H, et al. 2001. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61:8375–80.
109. Estecio MR, Yan PS, Ibrahim AE, et al. 2007. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 17:1529–36.
110. Hayashi H, Nagae G, Tsutsumi S, et al. 2007. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 120:701–11.
111. Model F, Osborn N, Ahlquist D, et al. 2007. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 5:153–63.
112. Yan PS, Efferth T, Chen HL, et al. 2002. Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods 27:162–9.
113. Cottrell S, Jung K, Kristiansen G, et al. 2007. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177:1753–8.
114. Wang Y, Yu Q, Cho AH, et al. 2005. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 7:748–60.
115. Yu YP, Paranjpe S, Nelson J, et al. 2005. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 26:471–9.
116. Fukasawa M, Kimura M, Morita S, et al. 2006. Microarray analysis of promoter methylation in lung cancers. J Hum Genet 51:368–74.
117. Rauch T, Li H, Wu X, Pfeifer GP. 2006. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res 66:7939–47.
118. Rauch T, Wang Z, Zhang X, et al. 2007. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 104:5527–32.
119. Ordway JM, Bedell JA, Citek RW, et al. 2006. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 27:2409–23.
120. Pfister S, Schlaeger C, Mendrzyk F, et al. 2007. Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res 35:e51.
121. Bjornsson HT, Brown LJ, Fallin MD, et al. 2007. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 99:1270–3.
122. Swerdlow SH, Campo E, Harris NL, et al. 2008. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
123. Guo J, Burger M, Nimmrich I, et al. 2005. Differential DNA methylation of gene promoters in small B-cell lymphomas. Am J Clin Pathol 124:430–9.
124. Rahmatpanah FB, Carstens S, Guo J, et al. 2006. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 20:1855–62.
125. Scholz C, Nimmrich I, Burger M, et al. 2005. Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann Hematol 84:236–44.
126. Shi H, Guo J, Duff DJ, et al. 2007. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 28:60–70.
127. Taylor KH, Pena-Hernandez KE, Davis JW, et al. 2007. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 67:2617–25.
128. van Doorn R, Zoutman WH, Dijkman R, et al. 2005. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23:3886–96.
129. Figueroa ME, Reimers M, Thompson RF, et al. 2008. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One 3:e1882.
130. Kuang SQ, Tong WG, Yang H, et al. 2008. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22:1529–38.
131. Jiang Y, Dunbar A, Gondek LP, et al. 2009. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–25.
132. Kroeger H, Jelinek J, Estecio MR, et al. 2008. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:1366–73.
133. Irizarry RA, Ladd-Acosta C, Wen B, et al. 2009. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178–86.
134. He L, Hannon GJ. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–31.
135. Miska EA. 2005. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15:563–8.
136. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–66.
137. Lu J, Getz G, Miska EA, et al. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834–8.
138. Cimmino A, Calin GA, Fabbri M, et al. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–9.
139. Johnson SM, Grosshans H, Shingara J, et al. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635–47.
140. Thomson JM, Newman M, Parker JS, et al. 2006. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 20:2202–7.
141. Saito Y, Liang G, Egger G, et al. 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435–43.
142. Lujambio A, Ropero S, Ballestar E, et al. 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67:1424–9.
143. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. 2009. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69:4443–53.
144. Roman-Gomez J, Agirre X, Jimenez-Velasco A, et al. 2009. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol 27:1316–22.
145. Lujambio A, Calin GA, Villanueva A, et al. 2008. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556–61.
146. Keshet I, Schlesinger Y, Farkash S, et al. 2006. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 38:149–53.
147. Ohm JE, Baylin SB. 2007. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle 6:1040–3.
148. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. 2003. Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA 100:12253–8.
149. Frigola J, Song J, Stirzaker C, et al. 2006. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38:540–9.
150. Ehrich M, Turner J, Gibbs P, et al. 2008. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 105:4844–9.
151. Ohm JE, McGarvey KM, Yu X, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39:237–42.
152. Schlesinger Y, Straussman R, Keshet I, et al. 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39:232–6.
153. Widschwendter M, Fiegl H, Egle D, et al. 2007. Epigenetic stem cell signature in cancer. Nat Genet 39:157–8.
154. Feinberg AP, Ohlsson R, Henikoff S. 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33.
155. Rada-Iglesias A, Enroth S, Andersson R, et al. 2009. Histone H3 lysine 27 trimethylation in adult differentiated colon associated to cancer DNA hypermethylation. Epigenetics 4:107–13.
156. McCabe MT, Lee EK, Vertino PM. 2009. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res 69:282–91.
157. Toh Y, Ohga T, Endo K, et al. 2004. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 110:362–7.
158. Toh Y, Yamamoto M, Endo K, et al. 2003. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 10:333–8.
159. Yasui W, Oue N, Aung PP, et al. 2005. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8:86–94.
160. Faure AK, Pivot-Pajot C, Kerjean A, et al. 2003. Misregulation of histone acetylation in Sertoli cell-only syndrome and testicular cancer. Mol Hum Reprod 9:757–63.
161. Nouzova M, Holtan N, Oshiro MM, et al. 2004. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther 311:968–81.
162. Kang J, Zhang D, Chen J, Liu Q, Lin C. 2005. Antioxidants and trichostatin A synergistically protect against in vitro cytotoxicity of Ni2+ in human hepatoma cells. Toxicol In Vitro 19:173–82.
163. Biron VL, McManus KJ, Hu N, Hendzel MJ, Underhill DA. 2004. Distinct dynamics and distribution of histone methyl-lysine derivatives in mouse development. Dev Biol 276:337–51.
164. Sarg B, Koutzamani E, Helliger W, Rundquist I, Lindner HH. 2002. Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J Biol Chem 277:39195–201.
165. Tryndyak VP, Kovalchuk O, Pogribny IP. 2006. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 5:65–70.
166. Chen YX, Fang JY, Lu R, Qiu DK. 2007. Expression of p21(WAF1) is related to acetylation of histone H3 in total chromatin in human colorectal cancer. World J Gastroenterol 13:2209–13.
167. Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH, Qiu DK. 2004. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J Gastroenterol 10:2643–6.
168. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014–19.
169. Pruitt K, Zinn RL, Ohm JE, et al. 2006. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2:e40.
170. Kondo Y, Shen L, Cheng AS, et al. 2008. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:741–50.
171. Brena RM, Costello JF. 2007. Genome–epigenome interactions in cancer. Hum Mol Genet 16 Spec No 1:R96–R105.
172. Jones PA, Baylin SB. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–28.
173. Graff JR, Herman JG, Lapidus RG, et al. 1995. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195–9.
174. Li H, Ma X, Wang J, et al. 2007. Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc Natl Acad Sci USA 104:20001–6.
175. Rajasekhar VK, Begemann M. 2007. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25:2498–510.
176. Haupt Y, Bath ML, Harris AW, Adams JM. 1993. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 8:3161–4.
177. Jacobs JJ, Scheijen B, Voncken JW, et al. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678–90.
178. Jones PA, Martienssen R. 2005. A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Res 65:11241–6.
179. Esteller M. 2006. The necessity of a human epigenome project. Carcinogenesis 27:1121–5.
180. Rauscher FJ, 3rd. 2005. It is time for a Human Epigenome Project. Cancer Res 65:11229.
181. Jeltsch A, Walter J, Reinhardt R, Platzer M. 2006. German human methylome project started. Cancer Res 66:7378.
182. Garber K. 2006. Momentum building for human epigenome project. J Natl Cancer Inst 98:84–6.
183. Eckhardt F, Beck S, Gut IG, Berlin K. 2004. Future potential of the Human Epigenome Project. Expert Rev Mol Diagn 4:609–18.
184. Bradbury J. 2003. Human epigenome project – up and running. PLoS Biol 1:e82.
185. Rakyan VK, Hildmann T, Novik KL, et al. 2004. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol 2:e405.
186. Ball MP, Li JB, Gao Y, et al. 2009. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 27:361–8.
187. Deng J, Shoemaker R, Xie B, et al. 2009. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol 27:353–60.
188. Hodges E, Smith AD, Kendall J, et al. 2009. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Genome Res 19:1593–605.
189. Clarke J, Wu HC, Jayasinghe L, et al. 2009. Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol 4:265–70.